HIT Consultant October 21, 2024
Jasmine Pennic

What You Should Know:

Waltz Health, a digital health company specializing in medication pricing and distribution, and Noom, a leader in digital health and chronic disease prevention, have announced a unique partnership to provide employers and health plans with a comprehensive and affordable weight loss program.

– The collaboration will leverage Waltz Connect, Waltz Health’s innovative platform, to streamline access to GLP-1 medications, making them more accessible and cost-effective for employees.

Addressing the Rising Cost of Obesity

Obesity is a significant health concern with substantial economic implications. Studies estimate that overweight and obese workers cost U.S. businesses and employees a staggering $425.5 billion annually. While GLP-1 drugs have proven effective in treating obesity and related cardiovascular issues, their high...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article